Esmo 2021 – the jury remains out on CDK7 inhibition
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
World Lung 2021 – front-line competition lines up behind Keytruda
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
Esmo 2021 – Mirati bids to be belle of the ball
At a conference largely focused on big biopharma a few biotech catalysts stand out.
World Lung 2021 – Zepzelca salvages pride from the Atlantis wreckage
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
World Lung 2021 – treme stands up to scrutiny
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
World Lung 2021 preview – China challenges and tremelimumab rises
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
ESC 2021 – finerenone’s song gets a little sweeter
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
ESC 2021 – Jardiance blows Entresto out of the water
A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.
AAIC – speculative Alzheimer’s groups fail to catch the Aduhelm wave
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
